NewLink down 10% premarket

Shares of NewLink Genetics (NLNK) are poised for a down move at the open in apparent reaction to the company's announcement of the continuation of the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with surgically resected pancreatic cancer.

The interim analysis was conducted after the predetermined midpoint 222 patient events. A second interim analysis will be done after 333 patient events and, if necessary, a final analysis after 444 patient events.

The trial will involve as many as 722 patients.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs